Mitochondria at the Crossroads of Physiology and Pathology
Abstract
:1. Introduction
2. Cardiovascular Diseases
3. Inflammation
4. Aging
5. Neurodegeneration
6. Cancer
7. Conclusions
Conflicts of Interest
References
- Guerra, F.; Arbini, A.; Moro, L. Mitochondria and cancer chemoresistance. Biochim. Biophys. Acta (BBA) Bioenerg. 2017, 1858, 686–699. [Google Scholar] [CrossRef] [PubMed]
- Murphy, M.P. How mitochondria produce reactive oxygen species. Biochem. J. 2008, 417, 1–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Halestrap, A.P.; Pasdois, P. The role of the mitochondrial permeability transition pore in heart disease. Biochim. Biophys. Acta (BBA) Bioenerg. 2009, 1787, 1402–1415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jornayvaz, F.R.; Shulman, G.I. Regulation of mitochondrial biogenesis. Essays Biochem. 2010, 47, 69–84. [Google Scholar] [CrossRef] [Green Version]
- Tahrir, F.G.; Langford, D.; Amini, S.; Ahooyi, T.M.; Khalili, K. Mitochondrial quality control in cardiac cells: Mechanisms and role in cardiac cell injury and disease. J. Cell. Physiol. 2018, 234, 8122–8133. [Google Scholar] [CrossRef]
- Morciano, G.; Pedriali, G.; Sbano, L.; Iannitti, T.; Giorgi, C.; Pinton, P. Intersection of mitochondrial fission and fusion machinery with apoptotic pathways: Role of Mcl-1. Biol. Cell 2016, 108, 279–293. [Google Scholar] [CrossRef]
- Morciano, G.; Patergnani, S.; Bonora, M.; Pedriali, G.; Tarocco, A.; Bouhamida, E.; Marchi, S.; Ancora, G.; Anania, G.; Wieckowski, M.R.; et al. Mitophagy in Cardiovascular Diseases. J. Clin. Med. 2020, 9, 892. [Google Scholar] [CrossRef] [Green Version]
- Ding, W.-X.; Yin, X.-M. Mitophagy: Mechanisms, pathophysiological roles, and analysis. Biol. Chem. 2012, 393, 547–564. [Google Scholar] [CrossRef] [Green Version]
- Youle, R.J.; Van Der Bliek, A.M. Mitochondrial Fission, Fusion, and Stress. Science 2012, 337, 1062–1065. [Google Scholar] [CrossRef] [Green Version]
- Dai, W.; Jiang, L. Dysregulated Mitochondrial Dynamics and Metabolism in Obesity, Diabetes, and Cancer. Front. Endocrinol. 2019, 10, 570. [Google Scholar] [CrossRef] [Green Version]
- Chourasia, A.H.; Boland, M.L.; MacLeod, K. Mitophagy and cancer. Cancer Metab. 2015, 3, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bernardini, J.P.; Lazarou, M.; Dewson, G. Parkin and mitophagy in cancer. Oncogene 2016, 36, 1315–1327. [Google Scholar] [CrossRef]
- Fivenson, E.M.; Lautrup, S.H.; Sun, N.; Scheibye-Knudsen, M.; Stevnsner, T.V.; Nilsen, H.; A Bohr, V.; Fang, E.F. Mitophagy in neurodegeneration and aging. Neurochem. Int. 2017, 109, 202–209. [Google Scholar] [CrossRef] [PubMed]
- Luft, R.; Ikkos, D.; Palmieri, G.; Ernster, L.; Afzelius, B. A Case of Severe Hypermetabolism Of Nonthyroid Origin With A Defect In The Maintenance of Mitochondrial Respiratory Control: A Correlated Clinical, Biochemical, And Morphological Study. J. Clin. Investig. 1962, 41, 1776–1804. [Google Scholar] [CrossRef] [PubMed]
- Schapira, A.H. Mitochondrial diseases. Lancet 2012, 379, 1825–1834. [Google Scholar] [CrossRef]
- Circu, M.L.; Moyer, M.P.; Harrison, L.; Aw, T.Y. Contribution of glutathione status to oxidant-induced mitochondrial DNA damage in colonic epithelial cells. Free Radic. Biol. Med. 2009, 47, 1190–1198. [Google Scholar] [CrossRef] [Green Version]
- Rachek, L.I.; Yuzefovych, L.V.; LeDoux, S.P.; Julie, N.L.; Wilson, G.L. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol. Appl. Pharmacol. 2009, 240, 348–354. [Google Scholar] [CrossRef] [Green Version]
- Tait, S.W.; Green, D.R. Mitochondria and cell signalling. J. Cell Sci. 2012, 125, 807–815. [Google Scholar] [CrossRef] [Green Version]
- Guerra, F.; Guaragnella, N.; Arbini, A.; Bucci, C.; Giannattasio, S.; Moro, L. Mitochondrial Dysfunction: A Novel Potential Driver of Epithelial-to-Mesenchymal Transition in Cancer. Front. Oncol. 2017, 7, 295. [Google Scholar] [CrossRef] [Green Version]
- Srinivasan, S.; Guha, M.; Kashina, A.; Avadhani, N.G. Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection. Biochim. Biophys. Acta (BBA) Bioenerg. 2017, 1858, 602–614. [Google Scholar] [CrossRef]
- Chandel, N.S. Evolution of Mitochondria as Signaling Organelles. Cell Metab. 2015, 22, 204–206. [Google Scholar] [CrossRef] [Green Version]
- Drazic, A.; Myklebust, L.M.; Ree, R.; Arnesen, T. The world of protein acetylation. Biochim. Biophys. Acta (BBA) Proteins Proteom. 2016, 1864, 1372–1401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, S.; Min, K.-T. The Interface Between ER and Mitochondria: Molecular Compositions and Functions. Mol. Cells 2018, 41, 1000–1007. [Google Scholar] [PubMed]
- Pizzimenti, M.; Riou, M.; Charles, A.-L.; Talha, S.; Meyer, A.; Andrès, E.; Chakfé, N.; Lejay, A.; Geny, B. The Rise of Mitochondria in Peripheral Arterial Disease Physiopathology: Experimental and Clinical Data. J. Clin. Med. 2019, 8, 2125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bonora, M.; Wieckowski, M.R.; Sinclair, D.A.; Kroemer, G.; Pinton, P.; Galluzzi, L. Targeting mitochondria for cardiovascular disorders: Therapeutic potential and obstacles. Nat. Rev. Cardiol. 2018, 16, 33–55. [Google Scholar] [CrossRef] [PubMed]
- Rimessi, A.; Previati, M.; Nigro, F.; Wieckowski, M.R.; Pinton, P. Mitochondrial reactive oxygen species and inflammation: Molecular mechanisms, diseases and promising therapies. Int. J. Biochem. Cell Biol. 2016, 81, 281–293. [Google Scholar] [CrossRef]
- Zitvogel, L.; Kepp, O.; Galluzzi, L.; Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 2012, 13, 343–351. [Google Scholar] [CrossRef]
- Missiroli, S.; Genovese, I.; Perrone, M.; Vezzani, B.; Vitto, V.A.M.; Giorgi, C. The Role of Mitochondria in Inflammation: From Cancer to Neurodegenerative Disorders. J. Clin. Med. 2020, 9, 740. [Google Scholar] [CrossRef] [Green Version]
- Moro, L. Mitochondrial Dysfunction in Aging and Cancer. J. Clin. Med. 2019, 8, 1983. [Google Scholar] [CrossRef] [Green Version]
- Reiter, R.J.; Sharma, R.; Ma, Q.; Dominquez-Rodriguez, A.; Marik, P.E.; Abreu-Gonzalez, P. Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis. Med. Drug Discov. 2020, 6, 100044. [Google Scholar] [CrossRef]
- Zhang, J.-M.; An, J. Cytokines, Inflammation, and Pain. Int. Anesthesiol. Clin. 2007, 45, 27–37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [Google Scholar] [CrossRef] [Green Version]
- Coperchini, F.; Chiovato, L.; Croce, L.; Magri, F.; Rotondi, M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020, 53, 25–32. [Google Scholar] [CrossRef] [PubMed]
- Zhou, G.; Li, S.; Xia, J. Network-Based Approaches for Multi-omics Integration. Methods Mol. Biol. 2020, 2104, 469–487. [Google Scholar] [CrossRef]
- Shneider, A.; Kudriavtsev, A.; Vakhrusheva, A. Can melatonin reduce the severity of COVID-19 pandemic? Int. Rev. Immunol. 2020, 1–10. [Google Scholar] [CrossRef]
- Zhang, R.; Wang, X.; Ni, L.; Di, X.; Ma, B.; Niu, S.; Liu, C.; Reiter, R. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020, 250, 117583. [Google Scholar] [CrossRef]
- Salles, C. Correspondence COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020, 253, 117716. [Google Scholar] [CrossRef]
- Herrera, E.A.; Gonzalez-Candia, A. Comment on Melatonin as a potential adjuvant treatment for COVID-19. Life Sci. 2020, 253, 117739. [Google Scholar] [CrossRef]
- Sun, N.; Youle, R.J.; Finkel, T. The Mitochondrial Basis of Aging. Mol. Cell 2016, 61, 654–666. [Google Scholar] [CrossRef] [Green Version]
- O’Hara, R.; Tedone, E.; Ludlow, A.T.; Huang, E.; Arosio, B.; Mari, D.; Shay, J.W. Quantitative mitochondrial DNA copy number determination using droplet digital PCR with single-cell resolution. Genome Res. 2019, 29, 1878–1888. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Q.; Wang, J.; Levichkin, I.V.; Stasinopoulos, S.; Ryan, M.T.; Hoogenraad, N. A mitochondrial specific stress response in mammalian cells. EMBO J. 2002, 21, 4411–4419. [Google Scholar] [CrossRef] [PubMed]
- Melber, A.; Haynes, C.M. UPRmt regulation and output: A stress response mediated by mitochondrial-nuclear communication. Cell Res. 2018, 28, 281–295. [Google Scholar] [CrossRef] [PubMed]
- Sun, N.; Yun, J.; Liu, J.; Malide, D.; Liu, C.; Rovira, I.I.; Holmström, K.; Fergusson, M.M.; Yoo, Y.H.; Combs, C.A.; et al. Measuring In Vivo Mitophagy. Mol. Cell 2015, 60, 685–696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- García-Prat, L.; Martínez-Vicente, M.; Perdiguero, E.; Ortet, L.; Rodríguez-Ubreva, J.; Rebollo, E.; Ruiz-Bonilla, V.; Gutarra, S.; Ballestar, E.; Serrano, A.L.; et al. Autophagy maintains stemness by preventing senescence. Nature 2016, 529, 37–42. [Google Scholar] [CrossRef]
- Palikaras, K.; Lionaki, E.; Tavernarakis, N. Coordination of mitophagy and mitochondrial biogenesis during ageing in C. elegans. Nature 2015, 521, 525–528. [Google Scholar] [CrossRef] [PubMed]
- Onyango, I.G. Mitochondria in the pathophysiology of Alzheimer s and Parkinson s diseases. Front. Biosci. 2017, 22, 854–872. [Google Scholar] [CrossRef] [Green Version]
- Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R.L.; Atwood, C.S.; Johnson, A.B.; Kress, Y.; Vinters, H.V.; Tabaton, M.; et al. Mitochondrial Abnormalities in Alzheimer’s Disease. J. Neurosci. 2001, 21, 3017–3023. [Google Scholar] [CrossRef] [Green Version]
- Chen, Z.; Zhong, C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013, 108, 21–43. [Google Scholar] [CrossRef] [Green Version]
- Henchcliffe, C.; Beal, M.F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat. Clin. Pract. Neurol. 2008, 4, 600–609. [Google Scholar] [CrossRef]
- Lin, M.T.; Simon, D.K.; Ahn, C.H.; Kim, L.M.; Beal, M.F. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer’s disease brain. Hum. Mol. Genet. 2002, 11, 133–145. [Google Scholar] [CrossRef]
- Fang, E.F. Mitophagy and NAD+ inhibit Alzheimer disease. Autophagy 2019, 15, 1112–1114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Truban, D.; Hou, X.; Caulfield, T.R.; Fiesel, F.C.; Springer, W. PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson’s Disease Pathobiology? J. Park. Dis. 2017, 7, 13–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berenguer-Escuder, C.; Grossmann, D.; Massart, F.; Antony, P.M.; Burbulla, L.F.; Glaab, E.; Imhoff, S.; Trinh, J.; Seibler, P.; Grünewald, A.; et al. Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson’s Disease Patients. J. Clin. Med. 2019, 8, 2226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cardaci, S.; Ciriolo, M.R. TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. Int. J. Cell Biol. 2012, 2012, 161837. [Google Scholar] [CrossRef]
- Schmidt, C.; Sciacovelli, M.; Frezza, C. Fumarate hydratase in cancer: A multifaceted tumour suppressor. Semin. Cell Dev. Biol. 2020, 98, 15–25. [Google Scholar] [CrossRef]
- Marquez, J.; Flores, J.; Kim, A.H.; Nyamaa, B.; Nguyen, A.T.T.; Park, N.; Han, J. Rescue of TCA Cycle Dysfunction for Cancer Therapy. J. Clin. Med. 2019, 8, 2161. [Google Scholar] [CrossRef] [Green Version]
- Kalsbeek, A.M.F.; Chan, E.; Corcoran, N.M.; Hovens, C.M.; Hayes, V.M. Mitochondrial genome variation and prostate cancer: A review of the mutational landscape and application to clinical management. Oncotarget 2017, 8, 71342–71357. [Google Scholar] [CrossRef] [Green Version]
- Ishikawa, K.; Takenaga, K.; Akimoto, M.; Koshikawa, N.; Yamaguchi, A.; Imanishi, H.; Nakada, K.; Honma, Y.; Hayashi, J.-I. ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis. Science 2008, 320, 661–664. [Google Scholar] [CrossRef] [Green Version]
- Moro, L.; Arbini, A.A.; Yao, J.L.; Di Sant’Agnese, P.A.; Marra, E.; Greco, M. Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2. Cell Death Differ. 2009, 16, 571–583. [Google Scholar] [CrossRef] [Green Version]
- Arbini, A.; Guerra, F.; Greco, M.; Marra, E.; Gandee, L.; Xiao, G.; Lotan, Y.; Gasparre, G.; Hsieh, J.-T.; Moro, L. Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. Oncogenesis 2013, 2, e82. [Google Scholar] [CrossRef]
- Hsieh, C.-H.; Li, L.; Vanhauwaert, R.; Nguyen, K.T.; Davis, M.D.; Bu, G.; Wszolek, Z.K.; Wang, X. Miro1 Marks Parkinson’s Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson’s Models. Cell Metab. 2019, 30, 1131–1140. [Google Scholar] [CrossRef] [PubMed]
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moro, L. Mitochondria at the Crossroads of Physiology and Pathology. J. Clin. Med. 2020, 9, 1971. https://doi.org/10.3390/jcm9061971
Moro L. Mitochondria at the Crossroads of Physiology and Pathology. Journal of Clinical Medicine. 2020; 9(6):1971. https://doi.org/10.3390/jcm9061971
Chicago/Turabian StyleMoro, Loredana. 2020. "Mitochondria at the Crossroads of Physiology and Pathology" Journal of Clinical Medicine 9, no. 6: 1971. https://doi.org/10.3390/jcm9061971